The above list is not inclusive of all the possible information that will flow from ENZC.
It is just a glimpse of activities in the works. Also while all the Catalysts will not move the stock price up they will move ENZC forward.
That being said, regardless of what business a stock is in, RESULTS will move the stock price.
ENZC has a plan of operation, a business strategy, a dream or a mission as the company called it in their 2020 Year End Update. Based on the update we could see RESULTS sooner than later in the following areas:
1. PCOAB Accounting Firm DONE
2. Update on Texas A&M activities
3. Update on GMP production
What we know is what the company has told us, what we don’t know I suspect will make many go WOW.
By combining our expertise with outside professionals and trusted consultants, we have succeeded in less than three months in accomplishing each of these items - as well as others.
What we don’t know is the
“AS WELL AS OTHERS”
Gonna get BUSY up in here when we find out.
The newly combined entity ENZC (Enzolytics and Bioclonetics)is an unusual company in a sense it has patened technology that has gone virtually unused for decades due to the inability to get funding to do the proper trials to bring it to the marketplace and a VISIONARY realized the potential of creating successful therapeutics against infectious diseases thereby increasing the value of the Company's technology and the value of the Company through the combination the Enzolytics ITV-1 peptide in conjunction with BioClonetics' anti-HIV monoclonal antibodies.
We have a Medical Advisory board including our management team and Dr. Ronald Moss. Also the Company has recently confirmed plans to test its monoclonal antibodies at the University of Strasbourg, France, under the direction of Dr. Christiane Moog, Ph.D., Research Director at INSERM, University of Strasbourg, a leading specialist in conducting the preferred PBMC based in vitro neutralization assays protocol for anti-HIV monoclonal antibodies. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy, under the direction of a further expert in the field, Dr. Gabriella Scarlatti, M.D., Ph.D., Head of Viral Evolution and Transmission Unit at San Raffaele Scientific Institute.
“OUTSIDE Professionals and TRUSTED Consultants”
ENZC management is very focus to the mission they are trying to accomplish and at times very unpredictable as in the case of the filing of a provisional patent with the U.S. Patent Office on December 9, 2020 for a treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341.
“The things WE DON”T KNOW”
ENZC is moving at a fast pace as evident with the recent toxicity study. ENZC has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States.
Harry Zhabilov, CSO stated "Dr. Moss has been instrumental in guiding Enzolytics in our current efforts to bring our product to the US Market. This is a big step for our organization, and we hope to be able to use most if not all of the information from our already successful Clinical Trials in Bulgaria to speed our attempt to meet the requirements in the US for approval."
Market Data 
Markets 
AI
